Immunofixation Control Instructions for Use

Total Page：16

File Type：pdf, Size：1020Kb

Immunofixation Control Instructions for Use Queensway South, Team Valley Trading Estate, 9400 Gateshead, Tyne and Wear, NE11 0SD, United Kingdom Tel: +44 (0)191 482 8440 Fax: +44 (0)191 482 8442 Email: [email protected] Web: www.helena-biosciences.com Helena Biosciences Europe © 2019 Helena Laboratories (UK) Limited trading as Helena Biosciences Europe. All rights reserved. INTENDED PURPOSE The Immunofixation Control is intended for use as a quality control material. Good laboratory practices require that test procedures be monitored with materials containing known constituents in order to determine that the test reagents are performing correctly. The controls contain known IgG kappa, IgA lambda and IgM monoclonal proteins. The Immunofixation Control is designed so that a control for each antisera can be run on each gel. Following electrophoresis, the appropriate control is applied to a well at the end of an electrophoresis pattern area on the gel. Antisera applied to the antisera slots comes into contact with the control serum and an antigen / antibody reaction occurs between the monospecific antiserum and its specific immunoglobulin. An appropriate reaction is indicated by the appearance of a precipitin ring around each well of the completed gel. WARNINGS AND PRECAUTIONS The reagents contained in this kit are for in vitro diagnostic use only – DO NOT INGEST. Wear appropriate personal protective equipment when handling all kit components. Refer to the product safety declaration for the link to appropriate hazard and precautionary statements where applicable. Dispose of components in accordance with local regulations. Blood products have been screened and found negative (unless otherwise stated on the kit box or vial) for the presence of: Hepatitis B Antigen (HbsAg) HIV 1 antibody HIV 2 antibody HCV antibody However they should be handled with the same precautions as a human patient sample. COMPOSITION 1. IgG KAPPA (1 x 0.5mL) REF HL-3-2490SA 2. IgA LAMBDA (1 x 0.5mL) REF HL-3-2491SA 3. IgM (1 x 0.5mL) REF HL-3-2492SA The controls are prepared from human sera containing an IgG kappa monoclonal protein, IgA lambda monoclonal protein and an IgM monocolonal protein with sodium azide added as a preservative. RECONSTITUTION The controls are ready for use as packaged. STORAGE, SHELF-LIFE AND STABILITY 1. IgG KAPPA, IgA LAMBDA and IgM The controls should be stored at 2...8°C and are stable until the expiry date indicated on the label. HL-2-1407P-EN 2015/12(4) Immunofixation Control EN 2019-09-06 06:00:31 1 Signs of deterioration: The controls should be free of particulate matter and straw-yellow in colour. ITEMS REQUIRED BUT NOT PROVIDED This product is to be used in conjunction with: REF 100300 SAS-MX IFE-1 Kit REF 100400 SAS-MX IFE-2 Kit PROCEDURE 1. Refer to the appropriate kit Instructions for Use for detailed instructions. INTERPRETATION OF RESULTS Additional use of controls: Immunofixation Control also can be used to verify all phases of the procedure. The controls can be used as a patient sample and taken through every step of the procedure. Used in this manner the control can verify correct electrophoresis and the specificity and activity of the antisera. HL-2-1407P-EN 2015/12(4) Immunofixation Control EN 2019-09-06 06:00:31 2.

Copy Link

Recommended publications

Lactoferrin and Its Detection Methods: a Review
nutrients Review Lactoferrin and Its Detection Methods: A Review Yingqi Zhang, Chao Lu and Jin Zhang * Department of Chemical and Biochemical Engineering, University of Western Ontario, London, ON N6A 5B9, Canada; [email protected] (Y.Z.); [email protected] (C.L.) * Correspondence: [email protected] Abstract: Lactoferrin (LF) is one of the major functional proteins in maintaining human health due to its antioxidant, antibacterial, antiviral, and anti-inflammatory activities. Abnormal levels of LF in the human body are related to some serious diseases, such as inflammatory bowel disease, Alzheimer’s disease and dry eye disease. Recent studies indicate that LF can be used as a biomarker for diagnosis of these diseases. Many methods have been developed to detect the level of LF. In this review, the biofunctions of LF and its potential to work as a biomarker are introduced. In addition, the current methods of detecting lactoferrin have been presented and discussed. We hope that this review will inspire efforts in the development of new sensing systems for LF detection. Keywords: lactoferrin; biomarkers; immunoassay; instrumental analysis; sensor 1. Introduction Lactoferrin (known as lactotransferrin, LF), with a molecular weight of about 80 kDa, is a functional glycoprotein, which contains about 690 amino acid residues. It was first isolated from bovine milk by Sorensen in 1939 and was first isolated from human milk by Citation: Zhang, Y.; Lu, C.; Zhang, J. Johanson in 1960 [1,2]. The three-dimensional structure of LF has been unveiled by high Lactoferrin and Its Detection resolution X-ray crystallographic analysis, and it consists of two homologous globular lobes Methods: A Review.
[Show full text]
Spontaneous Reversal of Acquired Autoimmune Dysfibrinogenemia Probably Due to an Antiidiotypic Antibody Directed to an Interspec
Spontaneous reversal of acquired autoimmune dysfibrinogenemia probably due to an antiidiotypic antibody directed to an interspecies cross-reactive idiotype expressed on antifibrinogen antibodies. A Ruiz-Arguelles J Clin Invest. 1988;82(3):958-963. https://doi.org/10.1172/JCI113704. Research Article A young man with a long history of abnormal bleeding was seen in January 1985. Coagulation tests showed dysfibrinogenemia and an antifibrinogen autoantibody was demonstrable in his serum. This antibody, when purified, was capable of inhibiting the polymerization of normal fibrin monomers, apparently through binding to the alpha fibrinogen chain. 6 mo later the patient was asymptomatic, coagulation tests were normal, and the antifibrinogen autoantibody was barely detectable. At this time, affinity-purified autologous and rabbit antifibrinogen antibodies were capable of absorbing an IgG kappa antibody from the patient's serum, which reacted indistinctly with both autologous and xenogeneic antifibrinogen antibodies in enzyme immunoassays. It has been concluded that the patient's dysfibrinogenemia was the result of an antifibrinogen autoantibody, and that later on an anti-idiotype antibody, which binds an interspecies cross- reactive idiotype expressed on anti-human fibrinogen antibodies, inhibited the production of the antifibrinogen autoantibody which led to the remission of the disorder. Find the latest version: https://jci.me/113704/pdf Spontaneous Reversal of Acquired Autoimmune Dysfibrinogenemia Probably Due to an Antildiotypic Antibody Directed to an Interspecies Cross-reactive Idiotype Expressed on Antifibrinogen Antibodies Alejandro Ruiz-Arguelles Department ofImmunology, Laboratorios Clinicos de Puebla, Puebla, Puebla 72530, Mexico Abstract disorder. This anti-Id antibody was shown to react with xeno- geneic antifibrinogen antibodies, hence, its specificity is an A young man with a long history of abnormal bleeding was interspecies cross-reactive Id (IdX)' most likely encoded by seen in January 1985.
[Show full text]
Guidelines for Writing Examination Items (Questions)
Guidelines for Writing Examination Items (Questions) Enclosed are the content outlines for the Immunology certification examinations. The content outline specifies the breakdown of content and overall structure of the examination and indicates how many test questions are assigned to each topic area from a total of 70 questions. The content outline will guide you in creating new items to match certain topic areas. We would appreciate at least two (2) new items for each major roman numeral on the content outline(s). This means we are asking you to write two items for Roman numeral I, two items for Roman numeral II, and so on for each of the Roman numeral sections of the Content Outline. We would appreciate items submitted in advance, preferably no later than Tuesday, February 25, 2020. • Please use the “Item Writing Template” to create your new items. This is the proper format to be used for all items you submit. Font: Times New Roma. Font Size: 11 • Please identify the Content Outline position for each item (e.g., Chemistry Content Outline, Roman numeral I. “Proteins”, A. “Total Proteins” should be noted as “I.A.”). • New items must be multiple choice with four (4) possible answers. Remember to avoid "double negatives," "not" questions (e.g., "Which of the following is NOT true?"), and those allowing "all (or none) of the above," or "a and b" as a possible answer. • Each new item that you create must be accompanied with a reference [Author, Publication Year, Title, Edition, Page Number(s)] containing the correct answer. IMPORTANT: references must be from an AAB Review Manual, Governmental Regulations, Association or World Health Organization (WHO) Guidelines, or a text or manual published within the last six (6) years.
[Show full text]
Monoclonal Antibody Playbook
Federal Response to COVID-19: Monoclonal Antibody Clinical Implementation Guide Outpatient administration guide for healthcare providers 2 SEPTEMBER 2021 1 Introduction to COVID-19 Monoclonal Antibody Therapy 2 Overview of Emergency Use Authorizations 3 Site and Patient Logistics Site preparation Patient pathways to monoclonal administration 4 Team Roles and Responsibilities Leadership Administrative Clinical Table of 5 Monoclonal Antibody Indications and Administration Indications Contents Preparation Administration Response to adverse events 6 Supplies and Resources Infrastructure Administrative Patient Intake Administration 7 Examples: Sites of Administration and Staffing Patterns 8 Additional Resources 1 1. Introduction to Monoclonal Therapy 2 As of 08/13/21 Summary of COVID-19 Therapeutics 1 • No Illness . Health, no infections • Exposed Asymptomatic Infected . Scope of this Implementation Guide . Not hospitalized, no limitations . Monoclonal Antibodies for post-exposure prophylaxis (Casirivimab + Imdevimab (RGN)) – EUA Issued. • Early Symptomatic . Scope of this Implementation Guide . Not hospitalized, with limitations . Monoclonal Antibodies for treatment (EUA issued): Bamlanivimab + Etesevimab1 (Lilly) Casirivimab + Imdevimab (RGN) Sotrovimab (GSK/Vir) • Hospital Adminission. Treated with Remdesivir (FDA Approved) or Tocilizumab (EUA Issued) . Hospitalized, no acute medical problems . Hospitalized, not on oxygen . Hospitlaized, on oxygen • ICU Admission . Hospitalized, high flow oxygen, non-invasive ventilation
[Show full text]
Ab200015 Human Lactoferrin Simplestep ELISA® Kit
Version 1 Last updated 28 August 2019 ab200015 Human Lactoferrin SimpleStep ELISA® Kit For the quantitative measurement of Lactoferrin in human serum, plasma, milk, urine, saliva, and cell culture supernatants. This product is for research use only and is not intended for diagnostic use. Copyright © 2018 Abcam. All rights reserved Table of Contents 1. Overview 1 2. Protocol Summary 2 3. Precautions 3 4. Storage and Stability 3 5. Limitations 4 6. Materials Supplied 4 7. Materials Required, Not Supplied 5 8. Technical Hints 5 9. Reagent Preparation 7 10. Standard Preparation 8 11. Sample Preparation 9 12. Plate Preparation 11 13. Assay Procedure 12 14. Calculations 14 15. Typical Data 15 16. Typical Sample Values 16 17. Assay Specificity 23 18. Species Reactivity 23 19. Troubleshooting 24 20. Notes 25 Technical Support 26 Copyright © 2018 Abcam. All rights reserved 1. Overview Lactoferrin in vitro SimpleStep ELISA® (Enzyme-Linked Immunosorbent Assay) kit is designed for the quantitative measurement of Lactoferrin protein in humanserum, plasma, milk, urine, saliva, and cell culture supernatants. The SimpleStep ELISA® employs an affinity tag labeled capture antibody and a reporter conjugated detector antibody which immunocapture the sample analyte in solution. This entire complex (capture antibody/analyte/detector antibody) is in turn immobilized via immunoaffinity of an anti-tag antibody coating the well. To perform the assay, samples or standards are added to the wells, followed by the antibody mix. After incubation, the wells are washed to remove unbound material. TMB Development Solution is added and during incubation is catalyzed by HRP, generating blue coloration. This reaction is then stopped by addition of Stop Solution completing any color change from blue to yellow.
[Show full text]
El Paso Community College Syllabus Part II Official Course Description
MLAB 1235; Revised Fall 2019/Spring 2020 El Paso Community College Syllabus Part II Official Course Description SUBJECT AREA Medical Laboratory Technology COURSE RUBRIC AND NUMBER MLAB 1235 COURSE TITLE Immunology/Serology COURSE CREDIT HOURS 2 1 : 3 Credits Lec Lab I. Catalog Description Provides an introduction to the theory and application of basic immunology, including the immune response, principles of antigen-antibody reactions, and the principles of serological procedures as well as quality control, quality assurance, and lab safety. A grade of “C” or better is required in this course to take the next course. Corequisite: MLAB 1260. (1:3). Lab fee. II. Course Objectives A. Unit I. Laboratory Operations Upon satisfactory completion of this unit, the student will be able to: 1. Demonstrate adherence to Standard Precautions and the organizations’ SOP (Standard Operating Procedures) at all times. 2. Discuss legal and ethical concerns pertaining to Patient Informed Consent, Standard of Care, and HIPAA regulations. 3. Compliance with government, state, and organizational safety regulations involving Biological, Chemical, Radioactive, Fire, Physical, and Electrical hazards. 4. Explain the importance of actively participating in Quality Assurance, Quality Control and Proficiency Testing protocols incorporating precision, accuracy, Levi Jennings Charts and Westgard Rules. 5. Locate and make use of MSDS (Material Safety Data Sheets) 6. Discuss how OSHA affects safety, health, and compliance policies in the workplace. 7. Discuss nosocomial infections and identify the basic programs for infection control. 8. Identify the potential routes of infection and methods for preventing transmission of microorganisms through these routes. 9. Explain the proper techniques for hand washing, gowning, gloving, and masking.
[Show full text]
Tests for Autoimmune Diseases Test Codes 249, 16814, 19946
Tests for Autoimmune Diseases Test Codes 249, 16814, 19946 Frequently Asked Questions Panel components may be ordered separately. Please see the Quest Diagnostics Test Center for ordering information. 1. Q: What are autoimmune diseases? A: “Autoimmune disease” refers to a diverse group of disorders that involve almost every one of the body’s organs and systems. It encompasses diseases of the nervous, gastrointestinal, and endocrine systems, as well as skin and other connective tissues, eyes, blood, and blood vessels. In all of these autoimmune diseases, the underlying problem is “autoimmunity”—the body’s immune system becomes misdirected and attacks the very organs it was designed to protect. 2. Q: Why are autoimmune diseases challenging to diagnose? A: Diagnosis is challenging for several reasons: 1. Patients initially present with nonspecific symptoms such as fatigue, joint and muscle pain, fever, and/or weight change. 2. Symptoms often flare and remit. 3. Patients frequently have more than 1 autoimmune disease. According to a survey by the Autoimmune Diseases Association, it takes up to 4.6 years and nearly 5 doctors for a patient to receive a proper autoimmune disease diagnosis.1 3. Q: How common are autoimmune diseases? A: At least 30 million Americans suffer from 1 or more of the 80 plus autoimmune diseases. On average, autoimmune diseases strike three times more women than men. Certain ones have an even higher female:male ratio. Autoimmune diseases are one of the top 10 leading causes of death among women age 65 and under2 and represent the fourth-largest cause of disability among women in the United States.3 Women’s enhanced immune system increases resistance to infection, but also puts them at greater risk of developing autoimmune disease than men.
[Show full text]
A Challenging Case of Igd Kappa Multiple Myeloma Associated with Primary Amyloidosis: Importance of Serum Free Light Chains in M
L al of euk rn em u i o a J Journal of Leukemia García de Veas Silva JL et al, J Leuk 2014, 2:5 ISSN: 2329-6917 DOI: 10.4172/2329-6917.1000164 Case Report Open Access A Challenging Case of IgD Kappa Multiple Myeloma Associated With Primary Amyloidosis: Importance of Serum Free Light Chains in Monitoring Treatment Response and Disease Relapse José Luis García de Veas Silva1*, Carmen Bermudo Guitarte1, Paloma Menéndez Valladares1, Rafael Duro Millán2 and Johanna Carolina Rojas Noboa2 1Department of Clinical Biochemistry, Hospital Universitario Virgen Macarena, Sevilla, Spain 2Department of Hematology, Hospital Universitario Virgen Macarena, Sevilla, Spain *Corresponding author: José Luis García de Veas Silva, Laboratory of Proteins, Department of Clinical Biochemistry, Hospital Universitario Virgen Macarena, Sevilla, Spain, Tel: +034955008108; E-mail: [email protected] Rec date: Oct 10, 2014, Acc date: Oct 16, 2014; Pub date: Oct 24, 2014 Copyright: © 2014 García de Veas Silva JL, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Multiple Myeloma (MM) is a malignancy of B cells characterized by an atypical proliferation of plasma cells. IgD MM has a very low incidence (2% of total MM cases) and it´s characterized by an aggressive course and a worse prognosis than other subtypes. The serum free light chains (sFLC) are very important markers for monitoring patients with MM and other monoclonal gammopathies. When the sFLC are present in low concentrations, it is often difficult to detect them by conventional methods such as serum protein electrophoresis and serum immunofixation.
[Show full text]
Understanding the Immune System: How It Works
Understanding the Immune System How It Works U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH National Institute of Allergy and Infectious Diseases National Cancer Institute Understanding the Immune System How It Works U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH National Institute of Allergy and Infectious Diseases National Cancer Institute NIH Publication No. 03-5423 September 2003 www.niaid.nih.gov www.nci.nih.gov Contents 1 Introduction 2 Self and Nonself 3 The Structure of the Immune System 7 Immune Cells and Their Products 19 Mounting an Immune Response 24 Immunity: Natural and Acquired 28 Disorders of the Immune System 34 Immunology and Transplants 36 Immunity and Cancer 39 The Immune System and the Nervous System 40 Frontiers in Immunology 45 Summary 47 Glossary Introduction he immune system is a network of Tcells, tissues*, and organs that work together to defend the body against attacks by “foreign” invaders. These are primarily microbes (germs)—tiny, infection-causing Bacteria: organisms such as bacteria, viruses, streptococci parasites, and fungi. Because the human body provides an ideal environment for many microbes, they try to break in. It is the immune system’s job to keep them out or, failing that, to seek out and destroy them. Virus: When the immune system hits the wrong herpes virus target or is crippled, however, it can unleash a torrent of diseases, including allergy, arthritis, or AIDS. The immune system is amazingly complex. It can recognize and remember millions of Parasite: different enemies, and it can produce schistosome secretions and cells to match up with and wipe out each one of them.
[Show full text]
Datasheet: MCA2763 Product Details
Datasheet: MCA2763 Description: MOUSE ANTI HUMAN LACTOFERRIN Specificity: LACTOFERRIN Format: Purified Product Type: Monoclonal Antibody Clone: 2B8 Isotype: IgG1 Quantity: 0.2 mg Product Details Applications This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols. Yes No Not Determined Suggested Dilution Flow Cytometry Immunohistology - Frozen Immunohistology - Paraffin ELISA Immunoprecipitation Western Blotting Functional Assays Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using the appropriate negative/positive controls. Target Species Human Product Form Purified IgG - liquid Preparation Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant Buffer Solution Phosphate buffered saline Preservative 0.09% Sodium Azide (NaN ) Stabilisers 3 Approx. Protein 1.0mg/ml Concentrations Immunogen Purified Lactoferrin from human milk. External Database UniProt: Links P02788 Related reagents Page 1 of 3 Entrez Gene: 4057 LTF Related reagents Synonyms LF Fusion Partners Spleen cells from immunised Balb/c mice were fused with cells of the Sp2/0 myeloma cell line. Specificity Mouse anti Human Lactoferrin antibody, clone 2B8 recognizes human lactoferrin, a ~80 kDa globular iron binding glycoprotein found in body secretions such as milk and saliva and is a member of the transferrin family proteins.
[Show full text]
Coverage of Monoclonal Antibody Products to Treat COVID-19
Coverage of Monoclonal Antibody Products to Treat COVID-19 Monoclonal antibody products to treat Coronavirus disease 2019 (COVID-19) help the body fight the virus or slow the virus’s growth. Medicare beneficiaries have coverage without beneficiary cost sharing for these products when used as authorized or approved by the Food and Drug Administration (FDA). Disclaimer: The contents of this document do not have the force and effect of law and are not meant to bind the public Medicare in any way, unless specifically incorporated into a contract. This document is intended only to provide clarity to the public regarding existing requirements under the law. This communication was printed, published, or produced and disseminated at U.S. taxpayer expense. Site of Care1 Payable by Expected Patient Expected Payment to Providers: Medicare Cost-Sharing Key Facts • Medicare payment for monoclonal antibody products to treat COVID-19 is similar across Inpatient No patient sites of care, with some small differences. Hospital cost-sharing • Medicare pays for the administration of monoclonal antibody products to treat COVID-19. For example, beginning on May 6, 2021, Medicare will pay approximately Outpatient $450 in most settings, or approximately $750 No patient in the beneficiary’s home or residence, for Hospital or cost-sharing the administration of certain monoclonal “Hospital 4 2 antibody products to treat COVID-19. For without Walls ” monoclonal antibody products to treat COVID-19 that are administered before May 6, 2021, the Medicare payment rate in all No patient settings is approximately $310. Outpatient cost-sharing3 Physician Office/ • CMS will exercise enforcement discretion to Infusion Center allow Medicare-enrolled immunizers working within their scope of practice and subject to applicable state law to bill directly and receive direct reimbursement from the Medicare program for administering Nursing Home monoclonal antibody treatments to No patient (See third bullet in Medicare Part A Skilled Nursing Facility Key Facts on CMS cost-sharing residents.
[Show full text]
Monoclonal Antibody Treatment for COVID-19
Monoclonal Antibody Treatment for COVID-19 Monoclonal antibody treatment is for people who have COVID-19 or were recently exposed to someone who has COVID-19, and are not hospitalized. Treatment can lower the amount of virus in your body, reduce symptoms and help avoid hospitalization. Treatment works best when you get it soon after COVID-19 symptoms begin, so it is important to get tested right away. What is monoclonal antibody treatment? How is monoclonal antibody Monoclonal antibodies are made in a lab and treatment given? work similarly to antibodies your immune Treatment is usually given by intravenous (IV) system makes to fight infection. Monoclonal infusion and takes about an hour. Treatment can antibody treatment helps your body fight also be given by injection. Patients are observed COVID-19 while your immune system begins for an additional hour to make sure they do not to make its own antibodies. In clinical studies, have any immediate bad reactions. monoclonal antibody treatments were shown to be safe and effective. What are the side effects? Side effects may include: Who is eligible for monoclonal antibody treatment? • A reaction at the site of the IV or injection, including pain, swelling, bleeding or bruising Treatment is authorized for people who meet all the following: • Nausea, vomiting or diarrhea • Itching, rash or hives Tested positive for COVID-19 Have had mild to moderate COVID-19 Allergic reactions and other serious side effects symptoms for 10 days or less are very rare. If you experience fever, trouble breathing, rapid or slow heart rate, tiredness, Are age 12 or older and weigh at least 88 pounds weakness, confusion, or other concerning symptoms, contact your provider right away.
[Show full text]